You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Fresh Perspectives on Geographic Atrophy: New Drugs and Latest Data

  • Authors: Mark Gillies, MBBS, PhD, FRANZCO​; Nicole Eter, MD; Anat Loewenstein, MD, MHA; Jordi Monés, MD, PhD; Ramin Tadayoni, MD, PhD​
  • CPD Released: 2/17/2022
  • Valid for credit through: 2/17/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.75 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US physicians caring for patients with advanced age-related macular degeneration (AMD), including ophthalmologists and primary care physicians.

The goal of this activity is to make physicians aware of the latest advances in geographic atrophy (GA), including new therapies and the latest data.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Burden of disease caused by GA secondary to AMD
    • Mechanism of action for emerging therapies in GA
    • Latest clinical data for emerging therapies in GA


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • Mark Gillies, MBBS, PhD, FRANZCO

    Director of Research
    The University of Sydney Save Sight Institute
    Faculty of Medicine and Health
    Sydney Eye Hospital
    Sydney, Australia

    Disclosures

    Independent contractor for: Novelty Nobility
    Grants for clinical research from: Bayer; Glaukos; Novartis; Roche

  • Nicole Eter, MD

    Professor and Chair
    Department of Ophthalmology
    University of Münster Medical Center
    Münster, Germany

    Disclosures

    Grants for clinical research from: Allergan; Bayer; Novartis
    Advisor or consultant for: Alcon; Allergan; Apellis; Bayer; Novartis; Roche
    Speaker or member of speakers bureau for: Allergan; Bayer; Novartis; Roche

  • Anat Loewenstein, MD, MHA

    Professor of Ophthalmology
    Deputy Dean
    Medical School
    Tel Aviv University
    Chairman
    Department of Ophthalmology
    Tel Aviv Sourasky Medical Center
    Tel Aviv, Israel

    Disclosures

    Grants for clinical research from: Notal Vision; Novartis; Roche
    Advisor or consultant for: Allergan; Bayer; Beyeonics; Notal Vision; Novartis; Roche
    Speaker or member of speakers bureau for: Allergan; Bayer; Novartis; Roche
    Stocks, stock options, or bonds from: Notal Vision
    Employed by an ineligible company: Notal Vision
    Ownership of an ineligible company: Notal Vision

  • Jordi Monés, MD, PhD

    Ophthalmologist, Macula and Vitreoretinal Specialist
    Director
    Institut de la Màcula and the Barcelona Macula Foundation
    Barcelona, Spain

    Disclosures

    Independent contractor for: Apellis; Ionics Pharmaceuticals; Iveric Bio; Kodiak Sciences; Novartis; ReNeuron; Roche
    Grants for clinical research from: Apellis; Ionics Pharmaceuticals; Iveric Bio; Kodiak Sciences; Novartis; ReNeuron; Roche
    Advisor or consultant for: Alexion; Apellis; Cell Cure; Ionics Pharmaceuticals; Iveric Bio; Kodiak Sciences; Lineage Cell Therapeutics; MacuLogix; Novartis; ReNeuron; Roche
    Speaker or member of speakers bureau for: Apellis; Cell Cure; Iveric Bio; Lineage Cell Therapeutics; MacuLogix; Novartis; ReNeuron; Roche
    Stocks, stock options, or bonds from: Iveric Bio; Notal Vision

  • Ramin Tadayoni, MD, PhD

    Professor of Ophthalmology
    Université de Paris
    Head of Ophthalmology
    Saint Louis Lariboisière and Adolphe de Rothschild Foundation Hospital
    Paris, France

    Disclosures

    Grants for clinical research from: AbbVie, Inc; Allergan; Bayer; Novartis
    Advisor or consultant for: AbbVie, Inc; Alcon Laboratories, Inc.; Allergan; Apellis; Bayer; Iveric Bio; KHB; Laboratoires THEA; Novartis; Oculis; Genentech; Roche
    Speaker or member of speakers bureau for: AbbVie, Inc.; Alcon Laboratories, Inc.; Allergan; Bayer; Genentech; Novartis; Roche
    Stocks, stock options, or bonds from: Oculis

Editor

  • Katherine Carpenter, PhD

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Katherine Carpenter, PhD has the following relevant financial relationships:
    Advisor or consultant for: Eisai, Inc.; GW Pharmaceuticals

Compliance Reviewer

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.75 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Fresh Perspectives on Geographic Atrophy: New Drugs and Latest Data

Authors: Mark Gillies, MBBS, PhD, FRANZCO​; Nicole Eter, MD; Anat Loewenstein, MD, MHA; Jordi Monés, MD, PhD; Ramin Tadayoni, MD, PhD​Faculty and Disclosures

CPD Released: 2/17/2022

Valid for credit through: 2/17/2023

processing....

Contents of This CPD Activity

All sections of this activity are required for credit.

Introduction

Dr Gillies explains why we should pay attention to GA, and he summarizes some recent developments.
Mark Gillies, MBBS, PhD, FRANZCO

Emerging Therapies and Mechanisms in Geographic Atrophy

Dr Tadayoni explains the complement system and mitochondrial protection as targets for GA treatment.
Ramin Tadayoni, MD, PhD

New Phase 3 Data in Geographic Atrophy

Dr Eter takes us through the first positive phase 3 data in GA.
Nicole Eter, MD

Interpretation of New Phase 3 Data in Geographic Atrophy

Dr Loewenstein and Dr Eter explore the data and its implications.
Anat Loewenstein, MD, MHA; Nicole Eter, MD

Earlier-Stage Developments in Geographic Atrophy

A summary of exciting new data on therapeutics in phase 1, 2, and 3 trials
Jordi Monés, MD, PhD

Conclusions

Take-home points from Dr Gillies
Mark Gillies, MBBS, PhD, FRANZCO
 

Educational Impact Challenge

The goal of this activity is to make physicians aware of the latest advances in geographic atrophy (GA), including new therapies and the latest data.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print